Market Currents
BioMarin's (BMRN -7.2%) recent secondary offers a buying opportunity ahead of the company's...
-
Thursday, May 31, 2012, 12:38 PM ETBioMarin's (BMRN -7.2%) recent secondary offers a buying opportunity ahead of the company's trial data releases, says Citigroup. Citi notes management comments stating that the financing is not intended to support any acquisitions in the near-term, which will give the company a cleaner balance sheet and leave its pipeline potentially well funded.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
